title: ERP grants first action status to candidate tissue residue methods for high-priority animal drugs.
authors.affiliation: Elanco Animal Health, 2500 Innovation Way, Greenfield, IN 46140, USA. coleman_mark_r@lilly.com
authors.forename: Mark R
authors.initials: MR
authors.lastname: Coleman
mesh_terms: D000818:Animals; D002623:Chemistry Techniques, Analytical / Q000379:methods; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D002853:Chromatography, Liquid / Q000379:methods; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry / Q000592:standards*; D004350:Drug Residues / Q000032:analysis*; D005104:Expert Testimony; D013058:Mass Spectrometry / Q000379:methods; D008985:Monensin / Q000032:analysis; D004364:Pharmaceutical Preparations / Q000032:analysis*; D010627:Phenethylamines / Q000032:analysis; D011714:Pyrans / Q000032:analysis; D015203:Reproducibility of Results; D014730:Veterinary Medicine / Q000379:methods / Q000592:standards
chemical_list: D004364:Pharmaceutical Preparations; D010627:Phenethylamines; D011714:Pyrans; C060897:ractopamine; D008985:Monensin; C013612:narasin